Absorbable Sutures 101
Absorbable sutures hold wound edges together while the body heals, then break down on their own. Because they do not need removal, they cut follow-up visits, reduce nursing time, and remove one step from the surgical workflow. That makes them a practical choice across departments.
Most absorbable sutures come from a small set of polymer families. Polyglycolic acid (PGA), its copolymers with lactic acid (PLGA), polydioxanone (PDS), and polylactic acid (PLA) dominate the market. Each family differs in how fast it loses strength and how surrounding tissue responds. One more bio-based family — PHA (polyhydroxyalkanoates) — sits at the research stage and is the subject of this guide.
Where PHA Fits in Suture Materials
PHA is a family of polyesters produced by bacterial fermentation. Unlike the PLA family, PHA-based materials are still at the evaluation stage for sutures. Polyhydroxybutyrate (PHB) and its copolymer PHBV have been studied as monofilament suture candidates, with studies of mechanical strength, degradation, and tissue response.
PHB monofilaments show useful tensile properties and degrade through both hydrolytic and enzymatic routes. Early evaluations report acceptable biocompatibility, which keeps PHA-based threads an active area of investigation. However, PHA sutures are not yet a market standard. The PLA family holds that position: polyglactin 910 (Vicryl) and poliglecaprone 25 (Monocryl) are FDA-cleared and used in operating rooms worldwide. The honest picture is that PHA is a promising candidate, not a current product category.
How Absorbable Suture Degradation Works
Most absorbable sutures lose strength through hydrolysis: water breaks the polymer chains into smaller fragments that the body metabolizes. The timeline is designed around wound healing. Most surgical wounds need support for roughly two to six weeks, so sutures retain tensile strength across that window, then dissolve.
Predictable degradation matters clinically. A suture that loses strength early risks wound dehiscence; one that persists too long can cause a prolonged foreign-body reaction. PHA-based materials tend to degrade more slowly than PGA or PLGA, which raises questions about matching their timeline to healing. That slower profile is not inherently a defect — it depends on the application — but it must be characterized before clinical use.
PHA vs PGA vs PLA Sutures
Procurement teams comparing options should weigh five factors:
- Tensile strength retention: PLA-family sutures retain strength predictably across the healing window; PHB monofilaments show adequate strength in studies, with less clinical history behind them.
- Degradation rate: PGA and PLGA degrade within weeks; PDS lasts longer; PHA-based materials degrade more slowly via hydrolysis and enzymes.
- Tissue reaction: Every absorbable polymer triggers a mild inflammatory response; FDA-cleared PLA-family products carry extensive biocompatibility data, while PHA suture data comes mainly from animal studies.
- Cost: PGA and PLA sutures benefit from decades of manufacturing scale; PHA production remains smaller and costlier.
- Availability: Vicryl, Monocryl, and PDS are stocked globally; no FDA-cleared PHA suture exists on the market.
That contrast separates an established category from an emerging one. For any of these materials, biocompatibility testing follows the ISO 10993 series, which sets the framework for evaluating tissue response before a device reaches clinical use.
Why Procurement Teams Should Care
Sustainability pressure is reaching the operating room. Single-use products generate substantial waste, and buyers are looking for materials that reduce environmental load without compromising clinical performance. PHA-based devices fit that direction: they are bio-based, biodegradable, and already used in non-suture applications.
For now, the practical move is to track the evidence. Watch for controlled clinical studies and regulatory clearances before changing suture contracts. Teams can act on adjacent categories in the meantime. CliniEco supplies PLA-based isolation gowns, a working example of bioplastics in the OR, alongside individually wrapped surgical masks and bouffant caps that support everyday sustainable supply choices. For a side-by-side comparison, see our guide to PHA vs PLA in healthcare supplies. Facilities comparing options can review PHA adoption, availability and cost in Canada.
Related reading
FAQ
Are PHA sutures available today? Not as FDA-cleared commercial products. PHA-based monofilaments remain at the research stage, with studies covering strength, degradation, and tissue response. Until regulatory clearance and clinical data accumulate, the PLA family stays the absorbable standard.
Do absorbable sutures need removal? No. They hydrolyze in the body over weeks or months, eliminating the removal visit and reducing follow-up appointments versus non-absorbable threads.
Is PHA strong enough for surgery? In studies, PHB monofilaments show tensile strength in a useful range, but strength retention over time and degradation behavior still need fuller characterization. Strength alone is not the deciding factor; healing-matched degradation is what earns a suture its place in the OR.
Sources: Chen GQ, Wu Q. The application of polyhydroxyalkanoates as tissue engineering materials. Biomaterials, 2005. Pillai CKS, Sharma CP. Absorbable polymeric surgical sutures: chemistry, production, properties, biodegradability and performance. Journal of Biomaterials Applications, 2010. Regulatory context: FDA-cleared polyglactin 910 (Vicryl), poliglecaprone 25 (Monocryl), polydioxanone (PDS); ISO 10993 series for biological evaluation of medical devices.
Related Reading
Explore more guides in this category:
0 comments